Legend Biotech (LEGN) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Legend Biotech (NASDAQ: LEGN):

• 12/17/2025 – Legend Biotech had its price target lowered by analysts at Cantor Fitzgerald from $75.00 to $74.00. They now have an “overweight” rating on the stock.
• 12/15/2025 – Legend Biotech had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/12/2025 – Legend Biotech had its price target lowered by analysts at Morgan Stanley from $83.00 to $50.00. They now have an “overweight” rating on the stock.
• 12/8/2025 – Legend Biotech had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Legend Biotech had its “outperform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $74.00 price target on the stock.
• 12/8/2025 – Legend Biotech had its price target lowered by analysts at UBS Group AG from $54.00 to $48.00. They now have a “buy” rating on the stock.
• 12/1/2025 – Legend Biotech had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/26/2025 – Legend Biotech had its “buy” rating reaffirmed by analysts at HC Wainwright.
• 11/24/2025 – Legend Biotech had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Legend Biotech had its price target lowered by analysts at Barclays PLC from $94.00 to $90.00. They now have an “overweight” rating on the stock.
• 11/13/2025 – Legend Biotech had its price target lowered by analysts at Royal Bank Of Canada from $75.00 to $74.00. They now have an “outperform” rating on the stock.
• 11/13/2025 – Legend Biotech had its price target raised by analysts at Cantor Fitzgerald from $66.00 to $75.00. They now have an “overweight” rating on the stock.

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.